Dr Gillies O’Bryan-Tear Joins Clarity Pharmaceuticals’ Board
Sydney, Australia 10 April 2019 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that Dr Gillies O’Bryan-Tear has joined Clarity’s Board following his recent appointment to their Scientific Advisory Board in August 2018 (Clarity Announcement dated 23 August 2018). Dr O’Bryan-Tear joined the pharmaceutical industry in…